banner ad

Pharmaceutical Pharmacology Consultant Esam Dajani

Esam Z. Dajani, Ph.D., FACG
1549 RFD
Long Grove IL 60047
phone: 847-634-9586; 847-971-7555
Professor Esam Z. Dajani, Ph.D., FACG is the President and Founder of IDDC Corporation, a contract research organization, that provides consulting services in Pharmacology, Toxicology, Therapeutics, Biotechnology, Drug Development, Pharmaceutical Patents and Regulatory Affairs to pharmaceutical companies, governmental agencies, and law firms. Professor Dajani is an experienced pharmacologist and toxicologist with extensive knowledge of all phases of drug discovery and development. With over 30 years of experience in pharmaceutical research and development, he has directed global clinical research at major multi-national pharmaceutical companies and led the research teams that discovered and developed misoprostol(Cytotec), a global anti-ulcer drug.

IDDC Corporation provides broad consulting services related to the development and successful registration of drugs, biological and medical devices. IDDC Corporation generates development plans and preliminary cost evaluation for product commercialization. IDDC Corporation provides consulting services for drug discovery and placement of pre-clinical pharmacology and toxicology and pharmaceutical development studies. IDDC Corporation assists the clients in the clinical development (Phases I-IV)and placement of clinical studies. IDDC selects the appropriate research facility at equitable price for the sponsors. IDDC prepares and reviews protocols design, clinical case report forms, study reports and summaries. The regulatory affairs consulting services include the preparation and filing of regulatory dossiers, e.g., IND's and NDA's. IDDC provides scientific reviews of new health care products and potential in-licensed products to pharmaceutical companies, venture capital firms and investment organizations.

View Expert Witness Profile.
2/20/2013 · Medical
It is well established that the use of traditional nonsteroidal anti-inflammatory drugs (NSAIDs) increases the vulnerability of the gastrointestinal (GI) mucosa for the development of peptic lesions and serious ulcer complications. In addition, selective and traditional NSAIDs have also been associated with increased frequency of cardiovascular toxicity, especially in susceptible patients.

12/14/2012 · Pharmaceuticals
During the last twenty-five years, a remarkable revolution in the pathophysiology and treatment of gastric (GU) and duodenal (DU) ulcers has occurred. Effective therapies were developed not only to heal ulcers but also to cure most patients.

Esam Z. Dajani, N.M. Agrawal
A chapter in the book: NSAIDs - Mechanisms and Clinical Use. Eds. Lewis AJ, Furst D, Marcel Dekker, New York, PP 159-170, 1994.
Esam Z. Dajani, H. Gallo-Torres
Chapter in the book: Ulcer Disease: Investigation And Basis For Therapy. Eds. Szabo S, Swabb E, Marcel Dekker, New York, PP 459-485, 1991
Esam Z. Dajani (ed.), Gabriele Bianchi Porro (ed.)
Esam Z. Dajani, PhD, FACG